Antinociceptive and antitumor activity of novel synthetic mononuclear Ruthenium (II) compounds.

Shyam Sunder A; Satyavati Dhulipala; Sreekanth Thota; Rajeshwar Yerra; Jan Balzarini; De Clercq Erik

Abstract

1 min read

These findings concluded that the new ruthenium compounds might be the promising antiproliferative agents as these compounds showing significant 5-LOX inhibitory activity and potential agents in the management of pain related disorders.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2013

Antinociceptive and antitumor activity of novel synthetic mononuclear Ruthenium (II) compounds

Angela Sünder, Satyavati Dhulipala, Sreekanth Thota, Rajeshwar Yerra, Jan Balzarini, De Clercq Erik

Article2010

Synthesis, characterization, antitumor, and cytotoxic activity of mononuclear Ru(II) complexes

Sreekanth Thota, Subhas S. Karki, Κ. N. Jayaveera, Jan Balzarini, De Clercq Erik

Article2000

Novel ribofuranosylnucleoside lead compounds for potent and selective inhibitors of mitochondrial thymidine kinase-2

Jan Balzarini, Chaoyong Zhu, De Clercq Erik, María‐Jesús Pérez‐Pérez, Christina CHAMORRO, Marı́a-José Camarasa, Anna Karlsson

Article2000

Novel ribofuranosylnucleoside lead compounds for potent and selective inhibitors of mitochondrial thymidine kinase-2

Jan Balzarini, Chaoyong Zhu, De Clercq Erik, María‐Jesús Pérez‐Pérez, Christina CHAMORRO, Marı́a-José Camarasa, Anna Karlsson

Article2021

Chemical Composition, Diuretic, and Antityrosinase Activity of Traditionally Used Romanian Cerasorum stipites

Mihai Babotă, Oliviu Voștinaru, Ramona Păltinean, Cosmin Mihali, María Inês Días, Lillian Barros, Isabel Cristina Fernandes Rodrigues Ferreira, Andrei Mocan, O. Crisan, Cristina Nicula, Gianina Crișan